All participants will receive a stable dose of MTX and in addition either adalimumab ( @ mg/@ @ ml for patients < @ kg or @ mg/@ @ ml for patients weighing @ kg or more , subcutaneous ( s/c ) injection every @ weeks based on body weight ) , or placebo ( @ ml as appropriate according to body weight ) s/c injection every @ weeks .